Louis M Mansky

List of Publications by Year
in descending order

75 papers	3,640 citations	196777 29 h-index	162838 57 g-index
80 all docs	80 docs citations	80 times ranked	4675 citing authors

#	Article	IF	Citations
1	Differential Activity of APOBEC3F, APOBEC3G, and APOBEC3H in the Restriction of HIV-2. Journal of Molecular Biology, 2022, 434, 167355.	2.0	6
2	Molecular Determinants of Human T-cell Leukemia Virus Type 1 Gag Targeting to the Plasma Membrane for Assembly. Journal of Molecular Biology, 2022, 434, 167609.	2.0	1
3	Human Retrovirus Genomic RNA Packaging. Viruses, 2022, 14, 1094.	1.5	15
4	Inhibiting HTLV-1 Protease: A Viable Antiviral Target. ACS Chemical Biology, 2021, 16, 529-538.	1.6	12
5	Development of a User-Friendly Pipeline for Mutational Analyses of HIV Using Ultra-Accurate Maximum-Depth Sequencing. Viruses, 2021, 13, 1338.	1.5	1
6	Distinct Antiretroviral Mechanisms Elicited by a Viral Mutagen. Journal of Molecular Biology, 2021, 433, 167111.	2.0	1
7	Structural Insights into the Mechanism of Human T-cell Leukemia Virus Type 1 Gag Targeting to the Plasma Membrane for Assembly. Journal of Molecular Biology, 2021, 433, 167161.	2.0	4
8	Sensitive Detection of Protein Binding to the Plasma Membrane with Dual-Color Z-Scan Fluorescence. Biophysical Journal, 2020, 118, 281-293.	0.2	4
9	Slow Receptor Binding of the Noncytopathic HIV-2UC1 Envs Is Balanced by Long-Lived Activation State and Efficient Fusion Activity. Cell Reports, 2020, 31, 107749.	2.9	14
10	Deamination hotspots among APOBEC3 family members are defined by both target site sequence context and ssDNA secondary structure. Nucleic Acids Research, 2020, 48, 1353-1371.	6.5	42
11	Effect of induced dNTP pool imbalance on HIV-1 reverse transcription in macrophages. Retrovirology, 2019, 16, 29.	0.9	6
12	Distinct dual antiviral mechanism that enhances hepatitis B virus mutagenesis and reduces viral DNA synthesis. Antiviral Research, 2019, 170, 104540.	1.9	3
13	Critical Role of the Human T-Cell Leukemia Virus Type 1 Capsid N-Terminal Domain for Gag-Gag Interactions and Virus Particle Assembly. Journal of Virology, 2018, 92, .	1.5	10
14	Distinct Pathway of Human T-Cell Leukemia Virus Type 1 Gag Punctum Biogenesis Provides New Insights into Enveloped Virus Assembly. MBio, 2018, 9, .	1.8	7
15	The HIV-1 Reverse Transcriptase A62V Mutation Influences Replication Fidelity and Viral Fitness in the Context of Multi-Drug-Resistant Mutations. Viruses, 2018, 10, 376.	1.5	10
16	Human T-cell leukemia virus type 1 Gag domains have distinct RNA-binding specificities with implications for RNA packaging and dimerization. Journal of Biological Chemistry, 2018, 293, 16261-16276.	1.6	9
17	The Retrovirus Capsid Core. Sub-Cellular Biochemistry, 2018, 88, 169-187.	1.0	4
18	Disparate Contributions of Human Retrovirus Capsid Subdomains to Gag-Gag Oligomerization, Virus Morphology, and Particle Biogenesis. Journal of Virology, 2017, 91, .	1.5	13

#	Article	IF	Citations
19	Polymorphic Nature of Human T-Cell Leukemia Virus Type 1 Particle Cores as Revealed through Characterization of a Chronically Infected Cell Line. Journal of Virology, 2017, 91, .	1.5	15
20	Single-Strand Consensus Sequencing Reveals that HIV Type but not Subtype Significantly Impacts Viral Mutation Frequencies and Spectra. Journal of Molecular Biology, 2017, 429, 2290-2307.	2.0	11
21	Perturbation of Human T-Cell Leukemia Virus Type 1 Particle Morphology by Differential Gag Co-Packaging. Viruses, 2017, 9, 191.	1.5	4
22	Molecular Studies of HTLV-1 Replication: An Update. Viruses, 2016, 8, 31.	1.5	41
23	Distinct Morphology of Human T-Cell Leukemia Virus Type 1-Like Particles. Viruses, 2016, 8, 132.	1.5	19
24	Distinct Particle Morphologies Revealed through Comparative Parallel Analyses of Retrovirus-Like Particles. Journal of Virology, 2016, 90, 8074-8084.	1.5	33
25	Dual anti-HIV mechanism of clofarabine. Retrovirology, 2016, 13, 20.	0.9	13
26	Synergistic reduction of HIV-1 infectivity by 5-azacytidine and inhibitors of ribonucleotide reductase. Bioorganic and Medicinal Chemistry, 2016, 24, 2410-2422.	1.4	14
27	5-Azacytidine Enhances the Mutagenesis of HIV-1 by Reduction to 5-Aza-2â€²-Deoxycytidine. Antimicrobial Agents and Chemotherapy, 2016, 60, 2318-2325.	1.4	10
28	Rapid Determination of HIV-1 Mutant Frequencies and Mutation Spectra Using an mCherry/EGFP Dual-Reporter Viral Vector. Methods in Molecular Biology, 2016, 1354, 71-88.	0.4	8
29	HIV-1 and HIV-2 exhibit similar mutation frequencies and spectra in the absence of G-to-A hypermutation. Retrovirology, 2015, 12, 60.	0.9	28
30	Morphology and ultrastructure of retrovirus particles. AIMS Biophysics, 2015, 2, 343-369.	0.3	52
31	Lack of Mutational Hot Spots during Decitabine-Mediated HIV-1 Mutagenesis. Antimicrobial Agents and Chemotherapy, 2015, 59, 6834-6843.	1.4	12
32	Analysis of Human T-Cell Leukemia Virus Type 1 Particles by Using Cryo-Electron Tomography. Journal of Virology, 2015, 89, 2430-2435.	1.5	23
33	Anti-HIV-1 activity of Trim 37. Journal of General Virology, 2014, 95, 960-967.	1.3	19
34	New insights into retroviral GagÃ¢â‚¬â€œGag and GagÃ¢â‚¬â€œmembrane interactions. Frontiers in Microbiology, 2014, 5, 302.	1.5	32
35	Retroviral Vectors for Analysis of Viral Mutagenesis and Recombination. Viruses, 2014, 6, 3612-3642.	1.5	4
36	Discovery of Novel Ribonucleoside Analogs with Activity against Human Immunodeficiency Virus Type 1. Journal of Virology, 2014, 88, 354-363.	1.5	21

#	Article	IF	Citations
37	Retrovirus-Specific Differences in Matrix and Nucleocapsid Protein-Nucleic Acid Interactions: Implications for Genomic RNA Packaging. Journal of Virology, 2014, 88, 1271-1280.	1.5	25
38	Novel inhibitors of human immunodeficiency virus type 2 infectivity. Journal of General Virology, 2014, 95, 2778-2783.	1.3	25
39	Interrelationship between Cytoplasmic Retroviral Gag Concentration and Gagâ€“Membrane Association. Journal of Molecular Biology, 2014, 426, 1611-1624.	2.0	34
40	Back to the future: revisiting HIV-1 lethal mutagenesis. Trends in Microbiology, 2013, 21, 56-62.	3.5	30
41	Structureâ€“Activity Relationships and Design of Viral Mutagens and Application to Lethal Mutagenesis. Journal of Medicinal Chemistry, 2013, 56, 9403-9414.	2.9	35
42	Interrelationship between HIV-1 Fitness and Mutation Rate. Journal of Molecular Biology, 2013, 425, 41-53.	2.0	35
43	5,6-Dihydro-5-aza-2â€²-deoxycytidine potentiates the anti-HIV-1 activity of ribonucleotide reductase inhibitors. Bioorganic and Medicinal Chemistry, 2013, 21, 7222-7228.	1.4	25
44	Variation of HIV-1 Mutation Spectra among Cell Types. Journal of Virology, 2013, 87, 5296-5299.	1.5	27
45	APOBEC3G cytosine deamination hotspots are defined by both sequence context and single-stranded DNA secondary structure. Nucleic Acids Research, 2013, 41, 6139-6148.	6.5	55
46	Anti-HIV-1 activity of resveratrol derivatives and synergistic inhibition of HIV-1 by the combination of resveratrol and decitabine. Bioorganic and Medicinal Chemistry Letters, 2012, 22, 6642-6646.	1.0	79
47	Discovery of drugs that possess activity against feline leukemia virus. Journal of General Virology, 2012, 93, 900-905.	1.3	20
48	Concomitant Lethal Mutagenesis of Human Immunodeficiency Virus Type 1. Journal of Molecular Biology, 2012, 419, 158-170.	2.0	19
49	Characterization of Cytoplasmic Gag-Gag Interactions by Dual-Color Z-Scan Fluorescence Fluctuation Spectroscopy. Biophysical Journal, 2011, 100, 1587-1595.	0.2	33
50	Analysis of the Ex Vivo and In Vivo Antiretroviral Activity of Gemcitabine. PLoS ONE, 2011, 6, e15840.	1.1	20
51	Analysis of the HTLV-1 Gag assembly pathway by biophysical fluorescence. Retrovirology, 2011, 8, .	0.9	2
52	New Insights into HTLV-1 Particle Structure, Assembly, and Gag-Gag Interactions in Living Cells. Viruses, 2011, 3, 770-793.	1.5	23
53	Biophysical analysis of HTLV-1 particles reveals novel insights into particle morphology and Gag stoichiometry. Retrovirology, 2010, 7, 75.	0.9	33
54	Viral Mutation Rates. Journal of Virology, 2010, 84, 9733-9748.	1.5	1,078

#	Article	IF	Citations
55	Exploiting Drug Repositioning for Discovery of a Novel HIV Combination Therapy. Journal of Virology, 2010, 84, 9301-9309.	1.5	85
56	APOBEC3G Contributes to HIV-1 Variation through Sublethal Mutagenesis. Journal of Virology, 2010, 84, 7396-7404.	1.5	161
57	5-Azacytidine Can Induce Lethal Mutagenesis in Human Immunodeficiency Virus Type 1. Journal of Virology, 2009, 83, 11950-11958.	1.5	88
58	Fluorescence Fluctuation Spectroscopy on Viral-Like Particles Reveals Variable Gag Stoichiometry. Biophysical Journal, 2009, 96, 1961-1969.	0.2	56
59	Human Immunodeficiency Virus Mutagenesis during Antiviral Therapy: Impact of Drug-Resistant Reverse Transcriptase and Nucleoside and Nonnucleoside Reverse Transcriptase Inhibitors on Human Immunodeficiency Virus Type 1 Mutation Frequencies. Journal of Virology, 2005, 79, 12045-12057.	1.5	30
60	Both the PPPY and PTAP Motifs Are Involved in Human T-Cell Leukemia Virus Type 1 Particle Release. Journal of Virology, 2004, 78, 1503-1512.	1.5	49
61	Vpr-mediated Incorporation of UNG2 into HIV-1 Particles Is Required to Modulate the Virus Mutation Rate and for Replication in Macrophages. Journal of Biological Chemistry, 2004, 279, 28419-28425.	1.6	111
62	A Role for dNTP Binding of Human Immunodeficiency Virus Type 1 Reverse Transcriptase in Viral Mutagenesis. Biochemistry, 2004, 43, 4490-4500.	1.2	53
63	Drug Resistance, Virus Fitness and HIV-1 Mutagenesis. Current Pharmaceutical Design, 2004, 10, 4065-4070.	0.9	41
64	Mutagenic outcome of combined antiviral drug treatment during human immunodeficiency virus type 1 replication. Virology, 2003, 307, 116-121.	1.1	27
65	Influence of Reverse Transcriptase Variants, Drugs, and Vpr on Human Immunodeficiency Virus Type 1 Mutant Frequencies. Journal of Virology, 2003, 77, 2071-2080.	1.5	77
66	Combination of Drugs and Drug-Resistant Reverse Transcriptase Results in a Multiplicative Increase of Human Immunodeficiency Virus Type 1 Mutant Frequencies. Journal of Virology, 2002, 76, 9253-9259.	1.5	42
67	HIV mutagenesis and the evolution of antiretroviral drug resistance. Drug Resistance Updates, 2002, 5, 219-223.	6.5	40
68	The Primary Nucleotide Sequence of the Bovine Leukemia Virus RNA Packaging Signal Can Influence Efficient RNA Packaging and Virus Replication. Virology, 2002, 301, 272-280.	1.1	18
69	In Vivo Analysis of Human T-Cell Leukemia Virus Type 1 Reverse Transcription Accuracy. Journal of Virology, 2000, 74, 9525-9531.	1.5	78
70	The Interaction of Vpr with Uracil DNA Glycosylase Modulates the Human Immunodeficiency Virus Type 1 In Vivo Mutation Rate. Journal of Virology, 2000, 74, 7039-7047.	1.5	167
71	3â€²-Azido-3â€²-Deoxythymidine (AZT) and AZT-Resistant Reverse Transcriptase Can Increase the In Vivo Mutation Rate of Human Immunodeficiency Virus Type 1. Journal of Virology, 2000, 74, 9532-9539.	1.5	79
72	In the beginning: genome recognition, RNA encapsidation and the initiation of complex retrovirus assembly. Journal of General Virology, 2000, 81, 1889-1899.	1.3	69

#	Article	IF	Citations
73	The Mutation Rate of Human Immunodeficiency Virus Type 1 Is Influenced by thevprGene. Virology, 1996, 222, 391-400.	1.1	120
74	Forward Mutation Rate of Human Immunodeficiency Virus Type 1 in a T Lymphoid Cell Line*. AIDS Research and Human Retroviruses, 1996, 12, 307-314.	0.5	121
75	Molecular Biology and Diversification of Human Retroviruses. Frontiers in Virology, 0, 2, .	0.7	2